Roche Holding AG started 2023 with a new CEO, Thomas Schinecker, and new Roche Pharmaceuticals CEO, Teresa Graham, during a year in which the Swiss-headquartered giant expected revenue to decline from 2022, largely due to disappearing COVID product revenue. However, Graham told Scrip in an interview at the recent J.P. Morgan Healthcare Conference, now that she has had a chance to look back at the past year, the company fared well overall and is in good shape for 2024 and beyond.
Key Takeaways
-
Roche is exiting a period of revenue declines due to COVID product sales drops and continuing a period of growth from new drugs and existing blockbusters.
There were three things she assessed at the end of last year that she said gave her confidence in where...
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
